u/heart_rate_bump

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

The scheme cap in Ireland was the single most useful thing I learned in a year of reading this board.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

phase 2 data only, and people quote it like it is a label

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

Sent an unusual compound to Medutest because nobody on this site had ever posted one. 98.3% against a claimed 97.5%.

Supply notices from the regulator describe expected availability at a national level. They do not predict what any individual pharmacy has on the shelf next week.

the TRIUMPH programme is still running, so anything definitive is premature

Push back: a private prescription is a separate route, not a shortcut through the NHS queue.

ApoB counts atherogenic particles rather than the cholesterol they carry, which is why it can diverge from LDL-C and why it is the addition most worth making.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

Asked QST which lines they keep in regional stock versus make to order and got a clear split. It changed what I ordered.

The three questions to ask before ordering anything from the long tail of a catalogue.

What exactly is it — catalogue number or sequence, not a common name, because several common names map to more than one molecule. How was identity established — mass against theoretical, ideally, rather than a bare purity figure. What are the storage conditions, stated specifically, with a state and a duration attached.

Then two commercial questions that save time: is this a stocked line or made to order, and what is the lead time in writing. All five are one email, and the shape of the reply tells you a great deal before any material moves.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

That is an escalation schedule for an unapproved compound and this board does not host those.

Same. My ICB threshold was different from the neighbouring one and nobody could tell me why.

Yes. Naming conventions in this corner are loose enough that the same word covers several different molecules.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

Nobody here can interpret your panel and this comment is not doing so. What a board can usefully do is help you ask better questions of somebody who can.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

Bought small because the evidence base is early. That is the only defensible position I could construct.

ask whether the lab changed its assay between your two draws

the escalation is where most of the reported trouble sits

the appendix is where the interesting tables live

Not convinced. A purity figure without a stated method is not comparable to one that has a method attached.

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

Net peptide content on the certificate was well below the purity figure and both were honest. Chemistry, not deception.

the ICB decides the threshold and they are not the same across England

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

Why the monthly pricing tracker works, and the rule that makes it work.

Members post the pharmacy, the product, the month and the price they actually paid — not an advertised offer, not a first-month discount. No links of any kind are permitted, which removes the entire incentive to post anything other than what happened.

The result is that the spread between pharmacies in a given month is visible, and it is consistently larger than people expect. That single table has saved members here more money than every other thread on the board combined, and it survives only because the no-links rule is enforced without exception.

Cosigning on baseline. The panel I regret most is the one I did not take before starting.

ask what the reference standard was

This is the rule for anything unusual. Identity before anything else.

Has anyone posted an independent test on this compound recently?

Bought small on anything without a testing history here. That rule has never once cost me anything.

Is that intention-to-treat or completers?

open-label extensions are not the same evidence as the randomised phase

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.